Johnston Michael C, Scott Christopher J
Centre for Cancer Research and Cell Biology, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7AE, United Kingdom.
Centre for Cancer Research and Cell Biology, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7AE, United Kingdom.
Drug Discov Today Technol. 2018 Dec;30:63-69. doi: 10.1016/j.ddtec.2018.10.003. Epub 2018 Nov 30.
Antibody conjugated nanoparticles (ACNPs) represent a novel strategy for the development of therapies exploiting antibodies to augment the delivery of chemotherapy payloads. Following in the footsteps of the success of antibody drug conjugates (ADCs), ACNPs are only now reaching clinical evaluation. In this review we discuss the success of ADCs and explore the opportunities ACNPs offer, such as broad chemotherapy payload selection, high drug to antibody ratios and the ability to finely tailor drug release in comparison to ADCs. The ability of ACNPs to elicit increased avidity due to multivalent effects and the potential to use these modular platforms in immunotherapeutic approaches is also explored. Through addressing challenges that still remain in bringing these complex formulations to the clinic, ACNPs hold obvious potential for the treatment of a wide range of cancers and other diseases where selective targeting of drug agents is essential.
抗体偶联纳米颗粒（ACNP）是一种利用抗体来增强化疗药物递送的新型治疗策略。继抗体药物偶联物（ADC）取得成功之后，ACNP目前才进入临床评估阶段。在本综述中，我们讨论了ADC的成功之处，并探讨了ACNP所带来的机遇，例如化疗药物选择范围广、药物与抗体比例高以及与ADC相比能够精确调控药物释放的能力。我们还探讨了ACNP因多价效应而引发亲和力增加的能力，以及在免疫治疗方法中使用这些模块化平台的潜力。通过应对将这些复杂制剂推向临床过程中仍然存在的挑战，ACNP在治疗多种癌症和其他疾病方面具有明显潜力，在这些疾病中，药物的选择性靶向至关重要。
